Immunomic Therapeutics receives FTD for ITI-3000 programme to treat Merkel Cell Carcinoma
Currently, the company is enrolling a Phase 1 trial analysing ITI-3000, a plasmid DNA (pDNA) vaccine targeting patients with MCC. MCC is a rare but aggressive form of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.